Friday, May 09, 2008 12:13:33 AM
Mon May 5, 2008 8:17am EDT
May 5 (Reuters) - Friedman Billings Ramsey upgraded Ev3 Inc (EVVV.O: Quote, Profile, Research) to "outperform" from "market perform," saying the medical device maker's shares should outperform in the next 12 months as the new chief executive executes on turning around the athrectomy business.
The brokerage, which has a price target of $12 on the stock, said the company's 2008 revenue outlook looks conservative and cost-cutting measures could make Ev3 profitable by the end of 2008.
Shares of Ev3 closed at $8.71 on Nasdaq Friday, when the company posted a wider-than-expected loss in the first quarter. (Reporting by Aditi Samajpati in Bangalore; Editing by Amitha Rajan)
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM